Abstract:The convenient and precise fabrication of drug-hydrogel formulations with satisfactory degradability and a well-controlled drug release profile are crucial factors for injectable hydrogel formulations in clinical applications. Here a new injectable thermosensitive hydrogel formed from poly(ε-caprolactone) (PCL)-poly(ethylene glycol)-poly(ε-caprolactone) amphiphilicco-polymers with 1,4,8-trioxa[4.6]spiro-9-undecanone (TOSUO) moieties incorporated in the poly(ε-caprolactone) (PCL)block (PECT) was constructed to provide a route to tailor the degradation and drug release behavior. The effect of hydrophilic cyclic ether moieties on the degradation of and drug release by PECT hydrogels were evaluated in vitro and in vivo. The results indicated that a freeze-dried powder of paclitaxel-loaded PECT nanoparticles rapidly dissolved in water at ambient temperature with slightly shaking and formed a stable injectable in situ drug-hydrogel formulation at body temperature, which is convenient for clinical operations because it avoids the need for pre-quenching or long-term incubation. The paclitaxel distribution was also more quantitative and homogeneous on entrapping paclitaxel in PECT nanoparticles. Further, the small number of pendant cyclic ether groups in PCL could decrease the cystallinity and hydrophobicity and, as a result, the in vitro and in vivo retention time of PECT hydrogels and the release of entrapped paclitaxel could be tuned from a few weeks to months by varying the amount of PTOSUO in the hydrophobic block. Significantly, paclitaxel-loaded PECT nanoparticles and free paclitaxel could be simultaneously released during the in vitro paclitaxel release from PECT hydrogels. A histopathological evaluation indicated that in vivo injected PECT hydrogels produced only a modest inflammatory response. Thus pendant cyclic ether modification of PCL could be an effective way to achieve the desired degradation and drug release profiles of amphiphilicco-polymer thermosensitive hydrogels and PECT hydrogels may be suitable for local drug delivery.

Controlled Directional Drug Release from Poly(ε-Caprolactone)/polyethylene Oxide/metoprolol Tartrate Composites with Multi-Layered Structures

Three-Dimensional Electrohydrodynamic Printing and Spinning of Flexible Composite Structures for Oral Multidrug Forms

Fabrication of Flexible Composite Drug Films Via Foldable Linkages Using Electrohydrodynamic Printing

Development of Random and Ordered Composite Fiber Hybrid Technologies for Controlled Release Functions

Controlled Engineering of Highly Aligned Fibrous Dosage Form Matrices for Controlled Release

The effect of layer thickness ratio on the drug release behavior of alternating layered composite prepared by layer-multiplying co-extrusion

Novel Hot Melt Extruded Matrices of Hydroxypropyl Cellulose and Amorphous Felodipine–Plasticized Hydroxypropyl Methylcellulose As Controlled Release Systems

Adjustable Degradation and Drug Release of a Thermosensitive Hydrogel Based on a Pendant Cyclic Ether Modified Poly(ε-Caprolactone) and Poly(ethylene Glycol)co-Polymer

Modulating Drug Release from Short Poly(ethylene Glycol) Block Initiated Poly(L-lactide) Di-block Copolymers

Delayed Sustained Drug Release from Electrostatic Powder Coated Tablets with Ultrafine Polymer Blends

CONTROLLED RELEASE OF SALICYLIC ACID FROM ELECTROSPUN MATS OF POLY(Ε-CAPROLACTONE) WITH LOW CRYSTALLINITY

Tissue lipid fatty acid composition of biotin-adequate and biotin-deficient chicks.

Sequence analysis of cDNA and genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding regulatory protein alpha subunit.

Multiblock Poly‐ε‐Caprolactones: One‐Step Synthesis Toward Programmable Properties

Facile Synthesis of Functional Poly( Ε -Caprolactone) Via Janus Polymerization

Influence of In Situ Calcium Pectinate Coating on Metoprolol Tartrate Pellets for Controlled Release and Colon-Specific Drug Delivery

Regulation of Biodegradability and Drug Release Behavior of Aliphatic Polyesters by Blending

Design of a core-shelled polymer cylinder for potential programmable drug delivery

A strategy to tailor the mechanical and degradation properties of PCL-PEG-PCL based copolymers for biomedical application

Reinforcement and Controlling the Stability of Poly(ε-caprolactone)-Based Polymeric Materials via Reversible and Movable Cross-Links Employing Cyclic Polyphenylene Sulfide

Preparation and Drug Sustained Release Behavior of Poly(ε-caprolactone)/Poly(ethylene Glycol)/poly(ε-Caprolactone) Amphiphilic Block Copolymeric Microspheres Containing Biological Macromolecule